Research and Studies
Weight loss drugs and hair loss: large study flags higher risk
BMJ study links GLP-1 weight loss medicines to more reports of non-scarring alopecia than other diabetes drugs.
By the Thicker Thinking Editorial Team
Published · 6 min read
Quick answerA BMJ study found people using GLP-1 weight loss medicines had more non-scarring hair loss diagnoses than those on other diabetes drugs. Regulators are reviewing signals, and clinicians advise discussing any shedding with your GP before changing treatment.
A large analysis published in the BMJ reports a higher rate of hair loss diagnoses among adults using GLP-1 receptor agonists, medicines widely used for diabetes and weight management. The findings renew questions about whether rapid weight loss and metabolic shifts could tip some people into temporary shedding.
Researchers compared people with type 2 diabetes on GLP-1 drugs with peers on two other common diabetes medicine classes. They found significantly more non-scarring alopecia in those on GLP-1s after adjusting for age, weight and other factors.
What happened
The team, including researchers from the University of Pennsylvania Health System, examined electronic health records to compare alopecia outcomes in two matched cohorts. One paired 12,004 GLP-1 users with 15,221 users of SGLT-2 inhibitors. The other paired 11,964 GLP-1 users with 11,233 users of DPP-4 inhibitors.
After statistical adjustment, GLP-1 use was associated with a 37% higher risk of alopecia versus SGLT-2 inhibitors. The risk was 68% higher compared with DPP-4 inhibitors. These figures describe relative differences between groups rather than an individual’s absolute chance of hair loss.
Further analysis suggested the signal related to non-scarring alopecia. In non-scarring types, hair follicles remain intact, so regrowth is possible once the trigger settles. That pattern aligns with temporary shedding conditions seen after physiological stress.
The researchers noted US regulators have been informed of hair loss reports, particularly for semaglutide and tirzepatide. They added that “the FDA is evaluating this potential safety signal,” a point they say warrants clinical awareness while evidence builds.
UK medicines safety data also reflect increased attention to this issue. According to The Independent, the MHRA has received 399 reports of hair loss relating to tirzepatide so far in 2026, on top of 541 last year, and 148 reports linked to semaglutide so far this year, alongside 164 last year.
GLP-1 medicines mimic gut hormones that help regulate blood sugar and appetite. In clinical practice they are prescribed for type 2 diabetes and, in some cases, for weight management in people meeting eligibility criteria.
The background
Dermatologists recognise that rapid weight change can push more hairs into the resting, shedding phase, a phenomenon called telogen effluvium. Calorie restriction and abrupt dietary shifts can also create short-term nutrient gaps that add to this risk.
The BMJ authors highlighted reduced caloric intake and micronutrient shortfalls, such as iron, zinc and biotin, as plausible contributors to shedding during GLP-1–associated weight loss. They also pointed to potential endocrine effects, including thyroid function changes, that could alter hair cycling.
GLP-1 drugs slow stomach emptying, which can affect the absorption of some oral medicines. The authors noted this could influence levels of thyroid or sex hormone therapies in certain people, and indirectly affect hair where hormonal balance is already sensitive.
Guidance from goodrx.com lists many medications that may cause hair thinning, from chemotherapy and some antidepressants to oral retinoids, anticoagulants and antithyroid drugs. It also notes hair loss with GLP-1s usually reflects weight loss itself rather than a direct effect of the medicine.
Not all shedding is a side effect of medication. Common conditions like androgenetic alopecia (pattern hair loss) or temporary shedding after illness or stress can overlap with treatment timelines. Our explainer on how much hair loss is normal — and when to worry outlines warning signs worth flagging to a clinician.
Nutritional factors are another piece of the puzzle. Low iron stores, inadequate protein intake and restricted diets can all influence hair growth. Our guide to protein deficiency and hair loss sets out when tests or dietary review may help.
Researchers are also beginning to document scalp changes during GLP-1 treatment beyond simple counting of shed hairs. Early work we covered in a recent GLP-1 shedding study suggests possible shifts in hair fibre properties and scalp symptoms, though evidence remains limited.
For context, we have previously summarised published and ongoing evidence in our primer on GLP-1 hair loss: what studies show and why it happens. Broadly, findings are mixed, data are still emerging, and individual responses vary considerably.
What people are saying
The BMJ paper emphasised that hair loss, while not physically harmful, can affect quality of life and adherence to treatment. It urged clinicians to discuss the possibility, monitor for shedding and consider reversible contributors such as nutrition and thyroid disease.
GoodRx advises that any medication-linked hair loss should be discussed with a prescriber before making changes. The service notes that hair often improves once the underlying trigger is addressed, which may include stabilising weight or correcting deficiencies.
Dermatologists generally advise against stopping a prescribed GLP-1 abruptly without medical input. They suggest reviewing the time course of shedding, checking ferritin and thyroid function when appropriate, and considering whether rapid weight change or intercurrent illness could be the main driver.
Specialists also recommend simple measures that support scalp health during periods of stress on the hair cycle. These include gentle hair care, avoiding tight styles or harsh chemical treatments, and ensuring adequate dietary protein alongside balanced iron and zinc intake.
For people with coexisting pattern hair loss, clinicians may discuss evidence-based options to maintain density while the temporary shedding settles. Any treatment choice should be individualised, and people are encouraged to speak to a GP, dermatologist or trichologist for tailored advice.
Psychological support can be helpful if shedding affects self-esteem or social confidence. Our guide on stress and hair loss explains how stress can worsen telogen effluvium and offers practical recovery timelines.
What happens next
Researchers say prospective studies are needed to pin down incidence, duration and risk factors for GLP-1–associated shedding. Key questions include whether pace of weight loss, baseline iron status, thyroid function or hormone therapy use change the risk.
Future analyses will likely examine whether hair regrowth tracks with weight stabilisation, and whether supportive measures reduce the likelihood of noticeable thinning. Robust patient-reported outcomes will be important to capture real-world impact.
Regulatory monitoring is ongoing. The US FDA is reviewing signals, and the UK MHRA continues to collect Yellow Card reports. Such reports flag potential issues but cannot on their own prove cause and effect, so formal studies will remain crucial.
For people experiencing sudden diffuse shedding after starting a GLP-1 medicine, clinicians recommend booking a review rather than stopping treatment unaided. A GP can assess for other causes, arrange tests if needed, and discuss whether treatment plans or weight targets should be adjusted.
Practical steps may include optimising dietary protein, checking iron stores where indicated, and ensuring other medicines, such as thyroid or sex hormone therapies, are absorbed and dosed appropriately. Over-the-counter supplements should only be started after professional advice.
The Independent also reports that these medicines have been linked with lower hospital admissions for alcohol dependence in separate datasets. Studies are exploring whether GLP-1s reduce alcohol intake, although evidence is still limited and mixed, and unrelated to hair outcomes.
As evidence develops, people on GLP-1s who notice increased shedding can be reassured that non-scarring hair loss often improves over months. Early conversations with a healthcare professional can help rule out other causes and set realistic expectations for recovery.
Why this matters
Many people in the UK now use GLP-1 medicines for diabetes or weight management. This study adds to early signals linking these drugs with temporary, non-scarring shedding. If you notice unusual hair loss after starting a GLP-1, it is worth speaking to your GP, dermatologist or trichologist. They can check for other causes, assess nutrition and thyroid health, and support a plan while hair cycles recover. Our overview of GLP-1 hair loss evidence explains current research and practical next steps.
Common questions
- do weight loss drugs like ozempic and wegovy cause hair loss
- They have been linked with more non-scarring hair loss diagnoses than some other diabetes drugs in a BMJ study. Shedding may relate to rapid weight loss and nutrition changes rather than a direct drug effect.
- which glp-1 drugs are linked to hair loss reports
- According to The Independent, UK regulators have received hair loss reports relating to tirzepatide and semaglutide. Researchers also noted US reports and ongoing FDA review.
- what did the bmj study find about hair loss risk
- GLP-1 users had a 37% higher alopecia risk than SGLT-2 users and a 68% higher risk than DPP-4 users, after adjustments. Signals pointed to non-scarring types.
- is hair loss from glp-1 drugs permanent
- Signals relate to non-scarring alopecia, which is usually temporary. Hair often regrows once triggers such as rapid weight loss or deficiencies are addressed.
- why might weight loss cause hair shedding
- Rapid weight change and reduced calorie intake can stress the hair cycle and create short-term gaps in iron, zinc or other nutrients, leading to telogen effluvium.
- should i stop my glp-1 if my hair is shedding
- Do not stop on your own. Speak to your GP or specialist to assess causes, review nutrition and other medicines, and agree any changes safely.
- are regulators investigating hair loss with glp-1 medicines
- Yes. The FDA is evaluating a potential safety signal, and the UK MHRA continues to collect Yellow Card reports on suspected side effects, including hair loss.
- do other medications also cause hair loss
- Yes. GoodRx lists several, including chemotherapy, some antidepressants, oral retinoids, anticoagulants and antithyroid drugs. Many cases improve after addressing the trigger.
Sources
- The Independent: Weight loss drugs linked to loss of hair in major new study | The Independent
- goodrx.com: 14 Medications That Cause Hair Loss - GoodRx
This article was written by Thicker Thinking using the sources listed above. It is for general information and is not medical advice. Speak to your GP, a dermatologist or a qualified trichologist about your own situation.
